Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 52, n° 3S
page P2 (mars 2005)
Doi : 10.1016/j.jaad.2004.10.021
Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept
 

Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA, United States; Alice Gottlieb, MD, PhD, UMDNJ—Robert Wood Johnson Medical Center, New Brunswick, NJ, United States; J. Michael Woolley, PhD, Amgen Inc., Thousand Oaks, CA, United States; Meleana Dunn, MS


 P5
Dr. Mease receives grant support from Amgen for conducting clinical trials and is a consultant for and a member of the speakers bureau for Amgen.
Research funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research.


Top of the page

© 2005  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@